The present disclosure relates to monoclonal anti-LINE-1 ORF2 protein endonuclease domain antibody, and fragments and derivatives that bind the LINE-1 ORF2 protein endonuclease domain and inhibit its activity.
Antibodies that inhibit long interspersed element-1 retrotransposon endonuclease activity